HPV Vaccination after Primary Treatment of HPV-Related Disease across Different Organ Sites: A Multidisciplinary Comprehensive Review and Meta-Analysis
To assess evidence on the efficacy of adjuvant human papillomavirus (HPV) vaccination in patients treated for HPV-related disease across different susceptible organ sites. A systematic review was conducted to identify studies addressing the efficacy of adjuvant HPV vaccination on reducing the risk o...
Saved in:
| Published in: | Vaccines (Basel) Vol. 10; no. 2; p. 239 |
|---|---|
| Main Authors: | , , , , , , , , , , , , , , , , , , , , , , , , , , |
| Format: | Journal Article |
| Language: | English |
| Published: |
Switzerland
MDPI AG
04-02-2022
MDPI |
| Subjects: | |
| Online Access: | Get full text |
| Tags: |
Add Tag
No Tags, Be the first to tag this record!
|
| Abstract | To assess evidence on the efficacy of adjuvant human papillomavirus (HPV) vaccination in patients treated for HPV-related disease across different susceptible organ sites.
A systematic review was conducted to identify studies addressing the efficacy of adjuvant HPV vaccination on reducing the risk of recurrence of HPV-related preinvasive diseases. Results were reported as mean differences or pooled odds ratios (OR) with 95% confidence intervals (95% CI).
Sixteen studies were identified for the final analysis. Overall, 21,472 patients with cervical dysplasia were included: 4132 (19.2%) received the peri-operative HPV vaccine, while 17,340 (80.8%) underwent surgical treatment alone. The recurrences of CIN 1+ (OR 0.45, 95% CI 0.27 to 0.73;
= 0.001), CIN 2+ (OR 0.33, 95% CI 0.20 to 0.52;
< 0.0001), and CIN 3 (OR 0.28, 95% CI 0.13 to 0.59;
= 0.0009) were lower in the vaccinated than in unvaccinated group. Similarly, adjuvant vaccination reduced the risk of developing anal intraepithelial neoplasia (
= 0.005) and recurrent respiratory papillomatosis (
= 0.004). No differences in anogenital warts and vulvar intraepithelial neoplasia recurrence rate were observed comparing vaccinated and unvaccinated individuals.
Adjuvant HPV vaccination is associated with a reduced risk of CIN recurrence, although there are limited data regarding its role in other HPV-related diseases. Further research is warranted to shed more light on the role of HPV vaccination as adjuvant therapy after primary treatment. |
|---|---|
| AbstractList | OBJECTIVETo assess evidence on the efficacy of adjuvant human papillomavirus (HPV) vaccination in patients treated for HPV-related disease across different susceptible organ sites. METHODSA systematic review was conducted to identify studies addressing the efficacy of adjuvant HPV vaccination on reducing the risk of recurrence of HPV-related preinvasive diseases. Results were reported as mean differences or pooled odds ratios (OR) with 95% confidence intervals (95% CI). RESULTSSixteen studies were identified for the final analysis. Overall, 21,472 patients with cervical dysplasia were included: 4132 (19.2%) received the peri-operative HPV vaccine, while 17,340 (80.8%) underwent surgical treatment alone. The recurrences of CIN 1+ (OR 0.45, 95% CI 0.27 to 0.73; p = 0.001), CIN 2+ (OR 0.33, 95% CI 0.20 to 0.52; p < 0.0001), and CIN 3 (OR 0.28, 95% CI 0.13 to 0.59; p = 0.0009) were lower in the vaccinated than in unvaccinated group. Similarly, adjuvant vaccination reduced the risk of developing anal intraepithelial neoplasia (p = 0.005) and recurrent respiratory papillomatosis (p = 0.004). No differences in anogenital warts and vulvar intraepithelial neoplasia recurrence rate were observed comparing vaccinated and unvaccinated individuals. CONCLUSIONSAdjuvant HPV vaccination is associated with a reduced risk of CIN recurrence, although there are limited data regarding its role in other HPV-related diseases. Further research is warranted to shed more light on the role of HPV vaccination as adjuvant therapy after primary treatment. To assess evidence on the efficacy of adjuvant human papillomavirus (HPV) vaccination in patients treated for HPV-related disease across different susceptible organ sites. A systematic review was conducted to identify studies addressing the efficacy of adjuvant HPV vaccination on reducing the risk of recurrence of HPV-related preinvasive diseases. Results were reported as mean differences or pooled odds ratios (OR) with 95% confidence intervals (95% CI). Sixteen studies were identified for the final analysis. Overall, 21,472 patients with cervical dysplasia were included: 4132 (19.2%) received the peri-operative HPV vaccine, while 17,340 (80.8%) underwent surgical treatment alone. The recurrences of CIN 1+ (OR 0.45, 95% CI 0.27 to 0.73; = 0.001), CIN 2+ (OR 0.33, 95% CI 0.20 to 0.52; < 0.0001), and CIN 3 (OR 0.28, 95% CI 0.13 to 0.59; = 0.0009) were lower in the vaccinated than in unvaccinated group. Similarly, adjuvant vaccination reduced the risk of developing anal intraepithelial neoplasia ( = 0.005) and recurrent respiratory papillomatosis ( = 0.004). No differences in anogenital warts and vulvar intraepithelial neoplasia recurrence rate were observed comparing vaccinated and unvaccinated individuals. Adjuvant HPV vaccination is associated with a reduced risk of CIN recurrence, although there are limited data regarding its role in other HPV-related diseases. Further research is warranted to shed more light on the role of HPV vaccination as adjuvant therapy after primary treatment. Objective: To assess evidence on the efficacy of adjuvant human papillomavirus (HPV) vaccination in patients treated for HPV-related disease across different susceptible organ sites. Methods: A systematic review was conducted to identify studies addressing the efficacy of adjuvant HPV vaccination on reducing the risk of recurrence of HPV-related preinvasive diseases. Results were reported as mean differences or pooled odds ratios (OR) with 95% confidence intervals (95% CI). Results: Sixteen studies were identified for the final analysis. Overall, 21,472 patients with cervical dysplasia were included: 4132 (19.2%) received the peri-operative HPV vaccine, while 17,340 (80.8%) underwent surgical treatment alone. The recurrences of CIN 1+ (OR 0.45, 95% CI 0.27 to 0.73; p = 0.001), CIN 2+ (OR 0.33, 95% CI 0.20 to 0.52; p < 0.0001), and CIN 3 (OR 0.28, 95% CI 0.13 to 0.59; p = 0.0009) were lower in the vaccinated than in unvaccinated group. Similarly, adjuvant vaccination reduced the risk of developing anal intraepithelial neoplasia (p = 0.005) and recurrent respiratory papillomatosis (p = 0.004). No differences in anogenital warts and vulvar intraepithelial neoplasia recurrence rate were observed comparing vaccinated and unvaccinated individuals. Conclusions: Adjuvant HPV vaccination is associated with a reduced risk of CIN recurrence, although there are limited data regarding its role in other HPV-related diseases. Further research is warranted to shed more light on the role of HPV vaccination as adjuvant therapy after primary treatment. Objective: To assess evidence on the efficacy of adjuvant human papillomavirus (HPV) vaccination in patients treated for HPV-related disease across different susceptible organ sites. Methods: A systematic review was conducted to identify studies addressing the efficacy of adjuvant HPV vaccination on reducing the risk of recurrence of HPV-related preinvasive diseases. Results were reported as mean differences or pooled odds ratios (OR) with 95% confidence intervals (95% CI). Results: Sixteen studies were identified for the final analysis. Overall, 21,472 patients with cervical dysplasia were included: 4132 (19.2%) received the peri-operative HPV vaccine, while 17,340 (80.8%) underwent surgical treatment alone. The recurrences of CIN 1+ (OR 0.45, 95% CI 0.27 to 0.73; p = 0.001), CIN 2+ (OR 0.33, 95% CI 0.20 to 0.52; p < 0.0001), and CIN 3 (OR 0.28, 95% CI 0.13 to 0.59; p = 0.0009) were lower in the vaccinated than in unvaccinated group. Similarly, adjuvant vaccination reduced the risk of developing anal intraepithelial neoplasia ( p = 0.005) and recurrent respiratory papillomatosis ( p = 0.004). No differences in anogenital warts and vulvar intraepithelial neoplasia recurrence rate were observed comparing vaccinated and unvaccinated individuals. Conclusions: Adjuvant HPV vaccination is associated with a reduced risk of CIN recurrence, although there are limited data regarding its role in other HPV-related diseases. Further research is warranted to shed more light on the role of HPV vaccination as adjuvant therapy after primary treatment. |
| Author | Cuccu, Ilaria Tanzi, Federica Mancino, Pasquale Valentini, Valentino Polimeni, Antonella Mingoli, Andrea Antonelli, Guido d'Ettorre, Gabriella Perniola, Giorgia Recine, Nadia Palaia, Innocenza Clementi, Ilaria Sorrenti, Sara Della Rocca, Carlo Di Donato, Violante Pierangeli, Alessandra Mastroianni, Claudio Maria Palaia, Gaspare Pernazza, Angelina de Vincentiis, Marco Caruso, Giuseppe Muzii, Ludovico Bogani, Giorgio Romeo, Umberto Cassoni, Andrea Cavallari, Eugenio Nelson Ralli, Massimo |
| AuthorAffiliation | 4 Department of Sense Organs, Sapienza University of Rome, Policlinico Umberto I, 00161 Rome, Italy; massimo.ralli@uniroma1.it 5 Department of Radiological, Oncological and Pathological Sciences, Sapienza University of Rome, Policlinico Umberto I, 00161 Rome, Italy; angelina.pernazza@uniroma1.it (A.P.); carlo.dellarocca@uniroma1.it (C.D.R.) 7 Department of Emergency, Sapienza University of Rome, Policlinico Umberto I, 00161 Rome, Italy; ilaria.clementi@uniroma1.it 8 Department of Surgery “Pietro Valdoni”, Sapienza University of Rome, Policlinico Umberto I, 00161 Rome, Italy; andrea.mingoli@uniroma1.it 1 Department of Maternal and Child Health and Urological Sciences, Sapienza University of Rome, Policlinico Umberto I, 00161 Rome, Italy; violante.didonato@uniroma1.it (V.D.D.); giorgio.bogani@uniroma1.it (G.B.); giorgia.perniola@uniroma1.it (G.P.); sara.sorrenti@uniroma1.it (S.S.); federica.tanzi@uniroma1.it (F.T.); ilaria.cuccu@uniroma1.it (I.C.); nadia.recine@uniroma1.it (N.R.); pasquale.m |
| AuthorAffiliation_xml | – name: 2 Department of Public Health and Infectious Diseases, Sapienza University of Rome, Policlinico Umberto I, 00161 Rome, Italy; eugenionelson.cavallari@uniroma1.it (E.N.C.); gabriella.dettorre@uniroma1.it (G.d.); claudio.mastroianni@uniroma1.it (C.M.M.) – name: 3 Department of Oral and Maxillofacial Sciences, Sapienza University of Rome, Policlinico Umberto I, 00161 Rome, Italy; gaspare.palaia@uniroma1.it (G.P.); umberto.romeo@uniroma1.it (U.R.); andrea.cassoni@uniroma1.it (A.C.); marco.devincentiis@uniroma1.it (M.d.V.); valentino.valentini@uniroma1.it (V.V.); antonella.polimeni@uniroma1.it (A.P.) – name: 6 Department of Molecular Medicine, Sapienza University of Rome, Policlinico Umberto I, 00161 Rome, Italy; alessandra.pierangeli@uniroma1.it (A.P.); guido.antonelli@uniroma1.it (G.A.) – name: 8 Department of Surgery “Pietro Valdoni”, Sapienza University of Rome, Policlinico Umberto I, 00161 Rome, Italy; andrea.mingoli@uniroma1.it – name: 1 Department of Maternal and Child Health and Urological Sciences, Sapienza University of Rome, Policlinico Umberto I, 00161 Rome, Italy; violante.didonato@uniroma1.it (V.D.D.); giorgio.bogani@uniroma1.it (G.B.); giorgia.perniola@uniroma1.it (G.P.); sara.sorrenti@uniroma1.it (S.S.); federica.tanzi@uniroma1.it (F.T.); ilaria.cuccu@uniroma1.it (I.C.); nadia.recine@uniroma1.it (N.R.); pasquale.mancino@uniroma1.it (P.M.); ludovico.muzii@uniroma1.it (L.M.); innocenza.palaia@uniroma1.it (I.P.) – name: 4 Department of Sense Organs, Sapienza University of Rome, Policlinico Umberto I, 00161 Rome, Italy; massimo.ralli@uniroma1.it – name: 7 Department of Emergency, Sapienza University of Rome, Policlinico Umberto I, 00161 Rome, Italy; ilaria.clementi@uniroma1.it – name: 5 Department of Radiological, Oncological and Pathological Sciences, Sapienza University of Rome, Policlinico Umberto I, 00161 Rome, Italy; angelina.pernazza@uniroma1.it (A.P.); carlo.dellarocca@uniroma1.it (C.D.R.) |
| Author_xml | – sequence: 1 givenname: Violante orcidid: 0000-0002-9254-5790 surname: Di Donato fullname: Di Donato, Violante organization: Department of Maternal and Child Health and Urological Sciences, Sapienza University of Rome, Policlinico Umberto I, 00161 Rome, Italy – sequence: 2 givenname: Giuseppe orcidid: 0000-0001-5501-1936 surname: Caruso fullname: Caruso, Giuseppe organization: Department of Maternal and Child Health and Urological Sciences, Sapienza University of Rome, Policlinico Umberto I, 00161 Rome, Italy – sequence: 3 givenname: Giorgio surname: Bogani fullname: Bogani, Giorgio organization: Department of Maternal and Child Health and Urological Sciences, Sapienza University of Rome, Policlinico Umberto I, 00161 Rome, Italy – sequence: 4 givenname: Eugenio Nelson orcidid: 0000-0002-6021-484X surname: Cavallari fullname: Cavallari, Eugenio Nelson organization: Department of Public Health and Infectious Diseases, Sapienza University of Rome, Policlinico Umberto I, 00161 Rome, Italy – sequence: 5 givenname: Gaspare orcidid: 0000-0001-8509-2255 surname: Palaia fullname: Palaia, Gaspare organization: Department of Oral and Maxillofacial Sciences, Sapienza University of Rome, Policlinico Umberto I, 00161 Rome, Italy – sequence: 6 givenname: Giorgia surname: Perniola fullname: Perniola, Giorgia organization: Department of Maternal and Child Health and Urological Sciences, Sapienza University of Rome, Policlinico Umberto I, 00161 Rome, Italy – sequence: 7 givenname: Massimo orcidid: 0000-0001-8776-0421 surname: Ralli fullname: Ralli, Massimo organization: Department of Sense Organs, Sapienza University of Rome, Policlinico Umberto I, 00161 Rome, Italy – sequence: 8 givenname: Sara surname: Sorrenti fullname: Sorrenti, Sara organization: Department of Maternal and Child Health and Urological Sciences, Sapienza University of Rome, Policlinico Umberto I, 00161 Rome, Italy – sequence: 9 givenname: Umberto orcidid: 0000-0003-2439-2187 surname: Romeo fullname: Romeo, Umberto organization: Department of Oral and Maxillofacial Sciences, Sapienza University of Rome, Policlinico Umberto I, 00161 Rome, Italy – sequence: 10 givenname: Angelina surname: Pernazza fullname: Pernazza, Angelina organization: Department of Radiological, Oncological and Pathological Sciences, Sapienza University of Rome, Policlinico Umberto I, 00161 Rome, Italy – sequence: 11 givenname: Alessandra orcidid: 0000-0003-0633-360X surname: Pierangeli fullname: Pierangeli, Alessandra organization: Department of Molecular Medicine, Sapienza University of Rome, Policlinico Umberto I, 00161 Rome, Italy – sequence: 12 givenname: Ilaria surname: Clementi fullname: Clementi, Ilaria organization: Department of Emergency, Sapienza University of Rome, Policlinico Umberto I, 00161 Rome, Italy – sequence: 13 givenname: Andrea orcidid: 0000-0001-5437-9085 surname: Mingoli fullname: Mingoli, Andrea organization: Department of Surgery "Pietro Valdoni", Sapienza University of Rome, Policlinico Umberto I, 00161 Rome, Italy – sequence: 14 givenname: Andrea orcidid: 0000-0001-6647-504X surname: Cassoni fullname: Cassoni, Andrea organization: Department of Oral and Maxillofacial Sciences, Sapienza University of Rome, Policlinico Umberto I, 00161 Rome, Italy – sequence: 15 givenname: Federica surname: Tanzi fullname: Tanzi, Federica organization: Department of Maternal and Child Health and Urological Sciences, Sapienza University of Rome, Policlinico Umberto I, 00161 Rome, Italy – sequence: 16 givenname: Ilaria surname: Cuccu fullname: Cuccu, Ilaria organization: Department of Maternal and Child Health and Urological Sciences, Sapienza University of Rome, Policlinico Umberto I, 00161 Rome, Italy – sequence: 17 givenname: Nadia surname: Recine fullname: Recine, Nadia organization: Department of Maternal and Child Health and Urological Sciences, Sapienza University of Rome, Policlinico Umberto I, 00161 Rome, Italy – sequence: 18 givenname: Pasquale surname: Mancino fullname: Mancino, Pasquale organization: Department of Maternal and Child Health and Urological Sciences, Sapienza University of Rome, Policlinico Umberto I, 00161 Rome, Italy – sequence: 19 givenname: Marco surname: de Vincentiis fullname: de Vincentiis, Marco organization: Department of Oral and Maxillofacial Sciences, Sapienza University of Rome, Policlinico Umberto I, 00161 Rome, Italy – sequence: 20 givenname: Valentino surname: Valentini fullname: Valentini, Valentino organization: Department of Oral and Maxillofacial Sciences, Sapienza University of Rome, Policlinico Umberto I, 00161 Rome, Italy – sequence: 21 givenname: Gabriella orcidid: 0000-0002-3571-5677 surname: d'Ettorre fullname: d'Ettorre, Gabriella organization: Department of Public Health and Infectious Diseases, Sapienza University of Rome, Policlinico Umberto I, 00161 Rome, Italy – sequence: 22 givenname: Carlo surname: Della Rocca fullname: Della Rocca, Carlo organization: Department of Radiological, Oncological and Pathological Sciences, Sapienza University of Rome, Policlinico Umberto I, 00161 Rome, Italy – sequence: 23 givenname: Claudio Maria orcidid: 0000-0002-1286-467X surname: Mastroianni fullname: Mastroianni, Claudio Maria organization: Department of Public Health and Infectious Diseases, Sapienza University of Rome, Policlinico Umberto I, 00161 Rome, Italy – sequence: 24 givenname: Guido surname: Antonelli fullname: Antonelli, Guido organization: Department of Molecular Medicine, Sapienza University of Rome, Policlinico Umberto I, 00161 Rome, Italy – sequence: 25 givenname: Antonella orcidid: 0000-0002-2679-7607 surname: Polimeni fullname: Polimeni, Antonella organization: Department of Oral and Maxillofacial Sciences, Sapienza University of Rome, Policlinico Umberto I, 00161 Rome, Italy – sequence: 26 givenname: Ludovico orcidid: 0000-0001-7195-9583 surname: Muzii fullname: Muzii, Ludovico organization: Department of Maternal and Child Health and Urological Sciences, Sapienza University of Rome, Policlinico Umberto I, 00161 Rome, Italy – sequence: 27 givenname: Innocenza surname: Palaia fullname: Palaia, Innocenza organization: Department of Maternal and Child Health and Urological Sciences, Sapienza University of Rome, Policlinico Umberto I, 00161 Rome, Italy |
| BackLink | https://www.ncbi.nlm.nih.gov/pubmed/35214697$$D View this record in MEDLINE/PubMed |
| BookMark | eNpdkk1PGzEQhq2KqtCUe0-VpV562dZee3e9PVSK0g-QQCBKUW-rWXscHG3Wqe2k4pf079YkgABf7PG883hmPK_J3uhHJOQtZx-FaNmnDWjtRoycsZKVon1BDkrW1IVoxe-9R-d9chjjguXVcqHq5hXZF1XJZd02B-Tf0fkVvdqSIDk_UrAJAz0Pbgnhhl4GhLTEMVFvaZYWFzhAQkO_uogQkYIOPsZsWovhVncW5jDSny5h_Eyn9HQ9JGdc1G415CcycuaXq4DXOEa3QXqBG4d_KYyGnmKCYjrCcBNdfENeWhgiHt7tE_Lr-7fL2VFxcvbjeDY9KbRsWSqgEqjLyuhGCqWayghjrVTIypIxYyvgbWuBc-C9lJKrHjmCtqLUNWrDmJiQ4x3XeFh0q13ZnQfXbS98mHcQktMDdgJ7WfYCjVCNNFKqHjSvreC1krbNngn5smOt1v0Sjc7tCDA8gT71jO66m_tNlzNva1llwIc7QPB_1hhTt8ydw2GAEf06dmUthJJKVSpL3z-TLvw65Obdq8pMzCq2U21_KaB9SIaz7naIuudDlEPePS7iIeB-ZMR_rVvIzg |
| CitedBy_id | crossref_primary_10_1016_j_ejogrb_2022_08_017 crossref_primary_10_3390_vaccines11020249 crossref_primary_10_3389_fonc_2024_1386167 crossref_primary_10_3390_encyclopedia3020036 crossref_primary_10_1097_CEJ_0000000000000896 crossref_primary_10_3390_pathogens13020163 crossref_primary_10_1002_jmv_29236 crossref_primary_10_3390_vaccines11030698 crossref_primary_10_26416_ObsGin_70_4_2022_7493 crossref_primary_10_3389_froh_2022_970074 crossref_primary_10_1097_LGT_0000000000000732 crossref_primary_10_1177_09691413231175630 crossref_primary_10_3390_vaccines11020284 crossref_primary_10_1016_j_rmclc_2024_03_003 crossref_primary_10_1186_s12879_023_08659_1 crossref_primary_10_1136_ijgc_2022_004213 crossref_primary_10_3390_v15071440 crossref_primary_10_1097_CEJ_0000000000000822 crossref_primary_10_1080_21645515_2024_2330168 crossref_primary_10_1089_hum_2023_066 crossref_primary_10_1016_j_revssu_2023_06_008 crossref_primary_10_1177_03008916231208344 crossref_primary_10_1097_AOG_0000000000005056 crossref_primary_10_3390_vaccines10040579 crossref_primary_10_3390_nu14214528 crossref_primary_10_25207_1608_6228_2022_29_3_103_120 crossref_primary_10_3390_vaccines11061060 crossref_primary_10_3390_vaccines11121850 |
| Cites_doi | 10.1038/s41541-020-0165-x 10.1016/j.ygyno.2013.04.050 10.1016/j.ijgo.2015.02.014 10.1016/j.jri.2015.01.002 10.1080/21645515.2015.1088616 10.1111/joim.13010 10.1002/ijc.32752 10.3390/vaccines8010045 10.1001/jamanetworkopen.2019.0819 10.1016/S1470-2045(10)70017-6 10.1016/j.ygyno.2018.08.033 10.1016/j.ygyno.2013.05.033 10.1097/01.AOG.0000187301.76283.7f 10.3390/vaccines8040717 10.1073/pnas.1714712114 10.3390/v11100922 10.1371/journal.pone.0069930 10.1186/s12879-018-3260-0 10.1002/ijc.30391 10.1186/s12889-020-8371-z 10.1016/j.bpobgyn.2020.02.009 10.1001/jamaoto.2016.4736 10.3390/vaccines8020245 10.1016/S2214-109X(19)30488-7 10.1016/j.vaccine.2012.07.056 10.1016/j.cmi.2015.05.001 10.1016/j.jcms.2010.11.001 10.3390/vaccines9020083 10.1016/j.ajog.2016.02.021 10.1080/21645515.2017.1407896 10.1016/j.ygyno.2020.08.025 10.1128/JVI.00093-14 10.1111/jsm.12670 10.1016/S1470-2045(14)70471-1 10.1002/ijc.30716 10.1016/j.ygyno.2007.08.059 10.3390/vaccines9050410 10.1016/j.virol.2008.10.004 10.1136/bmj.e1401 10.1093/cid/cir1036 10.1038/nrc.2018.13 10.1128/JVI.74.24.11636-11641.2000 10.1007/s00404-018-4926-y 10.1016/j.ygyno.2021.01.020 10.1016/j.ygyno.2020.08.034 10.15585/mmwr.mm6832a3 10.3390/v13071339 10.1016/j.vaccine.2018.09.027 |
| ContentType | Journal Article |
| Copyright | 2022 by the authors. Licensee MDPI, Basel, Switzerland. This article is an open access article distributed under the terms and conditions of the Creative Commons Attribution (CC BY) license (https://creativecommons.org/licenses/by/4.0/). Notwithstanding the ProQuest Terms and Conditions, you may use this content in accordance with the terms of the License. 2022 by the authors. 2022 |
| Copyright_xml | – notice: 2022 by the authors. Licensee MDPI, Basel, Switzerland. This article is an open access article distributed under the terms and conditions of the Creative Commons Attribution (CC BY) license (https://creativecommons.org/licenses/by/4.0/). Notwithstanding the ProQuest Terms and Conditions, you may use this content in accordance with the terms of the License. – notice: 2022 by the authors. 2022 |
| DBID | NPM AAYXX CITATION 3V. 7T7 7XB 8FD 8FE 8FH 8FK 8G5 ABUWG AFKRA AZQEC BBNVY BENPR BHPHI C1K CCPQU DWQXO FR3 GNUQQ GUQSH HCIFZ LK8 M2O M7P MBDVC P64 PIMPY PQEST PQQKQ PQUKI Q9U 7X8 5PM DOA |
| DOI | 10.3390/vaccines10020239 |
| DatabaseName | PubMed CrossRef ProQuest Central (Corporate) Industrial and Applied Microbiology Abstracts (Microbiology A) ProQuest Central (purchase pre-March 2016) Technology Research Database ProQuest SciTech Collection ProQuest Natural Science Collection ProQuest Central (Alumni) (purchase pre-March 2016) Research Library (Alumni Edition) ProQuest Central (Alumni) ProQuest Central ProQuest Central Essentials Biological Science Collection ProQuest Central ProQuest Natural Science Collection Environmental Sciences and Pollution Management ProQuest One Community College ProQuest Central Engineering Research Database ProQuest Central Student Research Library Prep SciTech Premium Collection (Proquest) (PQ_SDU_P3) Biological Sciences ProQuest research library Biological Science Database Research Library (Corporate) Biotechnology and BioEngineering Abstracts Publicly Available Content Database (Proquest) (PQ_SDU_P3) ProQuest One Academic Eastern Edition (DO NOT USE) ProQuest One Academic ProQuest One Academic UKI Edition ProQuest Central Basic MEDLINE - Academic PubMed Central (Full Participant titles) Directory of Open Access Journals |
| DatabaseTitle | PubMed CrossRef Publicly Available Content Database Research Library Prep ProQuest Central Student Technology Research Database ProQuest Central Essentials ProQuest Central (Alumni Edition) SciTech Premium Collection ProQuest One Community College Research Library (Alumni Edition) ProQuest Natural Science Collection Environmental Sciences and Pollution Management ProQuest Central Natural Science Collection ProQuest Central Korea Biological Science Collection ProQuest Research Library Industrial and Applied Microbiology Abstracts (Microbiology A) ProQuest Biological Science Collection ProQuest Central Basic ProQuest One Academic Eastern Edition Biological Science Database ProQuest SciTech Collection Biotechnology and BioEngineering Abstracts ProQuest One Academic UKI Edition Engineering Research Database ProQuest One Academic ProQuest Central (Alumni) MEDLINE - Academic |
| DatabaseTitleList | MEDLINE - Academic PubMed Publicly Available Content Database CrossRef |
| Database_xml | – sequence: 1 dbid: DOA name: Directory of Open Access Journals url: http://www.doaj.org/ sourceTypes: Open Website |
| DeliveryMethod | fulltext_linktorsrc |
| Discipline | Pharmacy, Therapeutics, & Pharmacology Public Health |
| EISSN | 2076-393X |
| ExternalDocumentID | oai_doaj_org_article_3eb42b3ed3874d448bac16f31684f92b 10_3390_vaccines10020239 35214697 |
| Genre | Journal Article Review |
| GroupedDBID | 3V. 53G 5VS 8FE 8FH 8G5 AADQD AAHBH ABUWG ADBBV AFKRA AFZYC ALMA_UNASSIGNED_HOLDINGS AOIJS AZQEC BBNVY BCNDV BENPR BHPHI BPHCQ CCPQU DIK DWQXO GNUQQ GROUPED_DOAJ GUQSH HCIFZ HYE IAO IHR ITC KQ8 LK8 M2O M48 M7P MODMG M~E NPM OK1 PGMZT PIMPY PQQKQ PROAC RIG RNS RPM AAYXX CITATION 7T7 7XB 8FD 8FK C1K FR3 MBDVC P64 PQEST PQUKI Q9U 7X8 5PM |
| ID | FETCH-LOGICAL-c490t-a53ec25dc7438875d3dff48e02200df5a199fa11a1b44418be1eacf32c6ecd003 |
| IEDL.DBID | RPM |
| ISSN | 2076-393X |
| IngestDate | Tue Oct 22 15:11:21 EDT 2024 Tue Sep 17 21:26:01 EDT 2024 Sat Oct 26 00:20:24 EDT 2024 Sat Nov 09 10:49:09 EST 2024 Fri Nov 22 02:44:25 EST 2024 Wed Oct 16 00:42:00 EDT 2024 |
| IsDoiOpenAccess | true |
| IsOpenAccess | true |
| IsPeerReviewed | true |
| IsScholarly | true |
| Issue | 2 |
| Keywords | laryngeal papillomatosis vulvar cancer human papillomavirus cervical cancer HPV anogenital warts vaccination |
| Language | English |
| License | Licensee MDPI, Basel, Switzerland. This article is an open access article distributed under the terms and conditions of the Creative Commons Attribution (CC BY) license (https://creativecommons.org/licenses/by/4.0/). |
| LinkModel | DirectLink |
| MergedId | FETCHMERGED-LOGICAL-c490t-a53ec25dc7438875d3dff48e02200df5a199fa11a1b44418be1eacf32c6ecd003 |
| Notes | ObjectType-Article-2 SourceType-Scholarly Journals-1 ObjectType-Feature-3 content type line 23 ObjectType-Review-1 |
| ORCID | 0000-0003-0633-360X 0000-0001-5501-1936 0000-0002-1286-467X 0000-0001-7195-9583 0000-0002-6021-484X 0000-0003-2439-2187 0000-0001-6647-504X 0000-0002-3571-5677 0000-0002-2679-7607 0000-0002-9254-5790 0000-0001-8509-2255 0000-0001-5437-9085 0000-0001-8776-0421 |
| OpenAccessLink | https://www.ncbi.nlm.nih.gov/pmc/articles/PMC8879645/ |
| PMID | 35214697 |
| PQID | 2633842964 |
| PQPubID | 2032320 |
| ParticipantIDs | doaj_primary_oai_doaj_org_article_3eb42b3ed3874d448bac16f31684f92b pubmedcentral_primary_oai_pubmedcentral_nih_gov_8879645 proquest_miscellaneous_2633848858 proquest_journals_2633842964 crossref_primary_10_3390_vaccines10020239 pubmed_primary_35214697 |
| PublicationCentury | 2000 |
| PublicationDate | 20220204 |
| PublicationDateYYYYMMDD | 2022-02-04 |
| PublicationDate_xml | – month: 2 year: 2022 text: 20220204 day: 4 |
| PublicationDecade | 2020 |
| PublicationPlace | Switzerland |
| PublicationPlace_xml | – name: Switzerland – name: Basel |
| PublicationTitle | Vaccines (Basel) |
| PublicationTitleAlternate | Vaccines (Basel) |
| PublicationYear | 2022 |
| Publisher | MDPI AG MDPI |
| Publisher_xml | – name: MDPI AG – name: MDPI |
| References | Kang (ref_21) 2013; 130 Mariz (ref_8) 2020; 5 Knobloch (ref_17) 2011; 39 Marur (ref_42) 2010; 11 ref_19 ref_18 Sand (ref_27) 2020; 147 Plummer (ref_47) 2017; 141 Ricci (ref_11) 2013; 130 Karita (ref_50) 2019; 2 Ault (ref_10) 2007; 107 Roden (ref_5) 2018; 18 Antonsson (ref_16) 2000; 74 Ndiaye (ref_41) 2014; 15 Ghelardi (ref_24) 2018; 151 Dion (ref_46) 2017; 143 Markowitz (ref_6) 2007; 56 ref_29 ref_28 Bogani (ref_37) 2021; 161 Meites (ref_4) 2019; 68 Athanasiou (ref_9) 2020; 65 Georges (ref_48) 2020; 8 Swedish (ref_34) 2012; 54 Ranjeva (ref_7) 2017; 114 Toft (ref_14) 2018; 14 Bogani (ref_36) 2021; 160 Garland (ref_22) 2016; 139 (ref_26) 2019; 40 Saftlas (ref_12) 2015; 109 ref_35 ref_33 ref_31 ref_30 Schneider (ref_45) 2018; 36 ref_39 Jones (ref_49) 2005; 106 Pils (ref_2) 2015; 21 Radley (ref_3) 2016; 12 Ma (ref_15) 2014; 88 Joura (ref_20) 2012; 344 Pieralli (ref_25) 2018; 298 Bogani (ref_38) 2020; 159 Coskuner (ref_32) 2014; 11 ref_43 Sankaranarayanan (ref_1) 2015; 131 Chesson (ref_51) 2012; 30 ref_40 Frazer (ref_13) 2009; 384 Du (ref_44) 2020; 287 Hildesheim (ref_23) 2016; 215 |
| References_xml | – volume: 5 start-page: 14 year: 2020 ident: ref_8 article-title: Peak neutralizing and cross-neutralizing antibody levels to human papillomavirus types 6/16/18/31/33/45/52/58 induced by bivalent and quadrivalent HPV vaccines publication-title: NPJ Vaccines doi: 10.1038/s41541-020-0165-x contributor: fullname: Mariz – volume: 130 start-page: 264 year: 2013 ident: ref_21 article-title: Is vaccination with quadrivalent HPV vaccine after loop electrosurgical excision procedure effective in preventing recurrence in patients with high-grade cervical intraepithelial neoplasia (CIN2–3)? publication-title: Gynecol. Oncol. doi: 10.1016/j.ygyno.2013.04.050 contributor: fullname: Kang – volume: 131 start-page: S33 year: 2015 ident: ref_1 article-title: HPV vaccination: The most pragmatic cervical cancer primary prevention strategy publication-title: Int. J. Gynecol. Obstet. doi: 10.1016/j.ijgo.2015.02.014 contributor: fullname: Sankaranarayanan – volume: 109 start-page: 74 year: 2015 ident: ref_12 article-title: Influence of a loop electrosurgical excision procedure (LEEP) on levels of cytokines in cervical secretions publication-title: J. Reprod. Immunol. doi: 10.1016/j.jri.2015.01.002 contributor: fullname: Saftlas – volume: 12 start-page: 768 year: 2016 ident: ref_3 article-title: Persistent infection with human papillomavirus 16 or 18 is strongly linked with high-grade cervical disease publication-title: Hum. Vaccines Immunother. doi: 10.1080/21645515.2015.1088616 contributor: fullname: Radley – volume: 287 start-page: 134 year: 2020 ident: ref_44 article-title: A global epidemic increase of an HPV-induced tonsil and tongue base cancer—Potential benefit from a pan-gender use of HPV vaccine publication-title: J. Intern. Med. doi: 10.1111/joim.13010 contributor: fullname: Du – volume: 147 start-page: 641 year: 2020 ident: ref_27 article-title: Risk of cervical intraepithelial neoplasia grade 2 or worse after conization in relation to HPV vaccination status publication-title: Int. J. Cancer doi: 10.1002/ijc.32752 contributor: fullname: Sand – ident: ref_28 doi: 10.3390/vaccines8010045 – volume: 2 start-page: e190819 year: 2019 ident: ref_50 article-title: Effect of Human Papillomavirus Vaccine to Interrupt Recurrence of Vulvar and Anal Neoplasia (VIVA): A Trial Protocol publication-title: JAMA Netw. Open doi: 10.1001/jamanetworkopen.2019.0819 contributor: fullname: Karita – volume: 11 start-page: 781 year: 2010 ident: ref_42 article-title: HPV-associated head and neck cancer: A virus-related cancer epidemic publication-title: Lancet Oncol. doi: 10.1016/S1470-2045(10)70017-6 contributor: fullname: Marur – volume: 151 start-page: 229 year: 2018 ident: ref_24 article-title: SPERANZA project: HPV vaccination after treatment for CIN2+ publication-title: Gynecol. Oncol. doi: 10.1016/j.ygyno.2018.08.033 contributor: fullname: Ghelardi – volume: 130 start-page: 642 year: 2013 ident: ref_11 article-title: HPV vaccine cross-protection: Highlights on additional clinical benefit publication-title: Gynecol. Oncol. doi: 10.1016/j.ygyno.2013.05.033 contributor: fullname: Ricci – volume: 106 start-page: 1319 year: 2005 ident: ref_49 article-title: Vulvar intraepithelial neoplasia: Aspects of the natural history and outcome in 405 women publication-title: Obstet. Gynecol. doi: 10.1097/01.AOG.0000187301.76283.7f contributor: fullname: Jones – ident: ref_30 doi: 10.3390/vaccines8040717 – volume: 114 start-page: 13573 year: 2017 ident: ref_7 article-title: Recurring infection with ecologically distinct HPV types can explain high prevalence and diversity publication-title: Proc. Natl. Acad. Sci. USA doi: 10.1073/pnas.1714712114 contributor: fullname: Ranjeva – ident: ref_40 doi: 10.3390/v11100922 – ident: ref_19 doi: 10.1371/journal.pone.0069930 – ident: ref_35 doi: 10.1186/s12879-018-3260-0 – volume: 139 start-page: 2812 year: 2016 ident: ref_22 article-title: For the HPV PATRICIA Study Group, Prior human papillomavirus-16/18 AS04-adjuvanted vaccination prevents recurrent high grade cervical intraepithelial neoplasia after definitive surgical therapy: Post-hoc analysis from a randomized controlled trial publication-title: Int. J. Cancer doi: 10.1002/ijc.30391 contributor: fullname: Garland – ident: ref_31 doi: 10.1186/s12889-020-8371-z – volume: 65 start-page: 109 year: 2020 ident: ref_9 article-title: HPV vaccination and cancer prevention publication-title: Best Pract. Res. Clin. Obstet. Gynaecol. doi: 10.1016/j.bpobgyn.2020.02.009 contributor: fullname: Athanasiou – volume: 143 start-page: 614 year: 2017 ident: ref_46 article-title: Adjuvant Human Papillomavirus Vaccination for Secondary Prevention: A Systematic Review publication-title: JAMA Otolaryngol.—Head Neck Surg. doi: 10.1001/jamaoto.2016.4736 contributor: fullname: Dion – ident: ref_29 doi: 10.3390/vaccines8020245 – volume: 8 start-page: e180 year: 2020 ident: ref_48 article-title: Global burden of cancer attributable to infections in 2018: A worldwide incidence analysis publication-title: Lancet Glob. Health doi: 10.1016/S2214-109X(19)30488-7 contributor: fullname: Georges – volume: 30 start-page: 6016 year: 2012 ident: ref_51 article-title: Estimates of the annual direct medical costs of the prevention and treatment of disease associated with human papillomavirus in the United States publication-title: Vaccine doi: 10.1016/j.vaccine.2012.07.056 contributor: fullname: Chesson – volume: 40 start-page: 402 year: 2019 ident: ref_26 article-title: Impact of the human papillomavirus vaccination on patients who underwent conization for high-grade cervical intraepithelial neoplasia publication-title: Eur. J. Gynaecol. Oncol. – volume: 21 start-page: 827 year: 2015 ident: ref_2 article-title: From the monovalent to the nine-valent HPV vaccine publication-title: Clin. Microbiol. Infect. doi: 10.1016/j.cmi.2015.05.001 contributor: fullname: Pils – volume: 39 start-page: 91 year: 2011 ident: ref_17 article-title: Preferred reporting items for systematic reviews and meta-analyses (PRISMA) statement and publication bias publication-title: J. Cranio-Maxillofac. Surg. doi: 10.1016/j.jcms.2010.11.001 contributor: fullname: Knobloch – ident: ref_33 doi: 10.3390/vaccines9020083 – volume: 215 start-page: 212.e1 year: 2016 ident: ref_23 article-title: Impact of human papillomavirus (HPV) 16 and 18 vaccination on prevalent infections and rates of cervical lesions after excisional treatment publication-title: Am. J. Obstet. Gynecol. doi: 10.1016/j.ajog.2016.02.021 contributor: fullname: Hildesheim – volume: 14 start-page: 909 year: 2018 ident: ref_14 article-title: Cellular immunogenicity of human papillomavirus vaccines Cervarix and Gardasil in adults with HIV infection publication-title: Hum. Vaccines Immunother. doi: 10.1080/21645515.2017.1407896 contributor: fullname: Toft – ident: ref_18 – volume: 159 start-page: 636 year: 2020 ident: ref_38 article-title: Recurrence rate after loop electrosurgical excision procedure (LEEP) and laser Conization: A 5-year follow-up study publication-title: Gynecol. Oncol. doi: 10.1016/j.ygyno.2020.08.025 contributor: fullname: Bogani – volume: 88 start-page: 4786 year: 2014 ident: ref_15 article-title: Human papillomavirus community in healthy persons, defined by metagenomics analysis of human microbiome project shotgun sequencing data sets publication-title: J. Virol. doi: 10.1128/JVI.00093-14 contributor: fullname: Ma – volume: 11 start-page: 2785 year: 2014 ident: ref_32 article-title: Impact of the quadrivalent HPV vaccine on disease recurrence in men exposed to HPV Infection: A randomized study publication-title: J. Sex. Med. doi: 10.1111/jsm.12670 contributor: fullname: Coskuner – volume: 56 start-page: 1 year: 2007 ident: ref_6 article-title: Centers for Disease Control and Prevention (CDC); Advisory Committee on Immunization Practices (ACIP): Quadrivalent Human Papillomavirus Vaccine: Recommendations of the Advisory Committee on Immunization Practices (ACIP) publication-title: MMWR Recomm. Rep. contributor: fullname: Markowitz – volume: 15 start-page: 1319 year: 2014 ident: ref_41 article-title: HPV DNA, E6/E7 mRNA, and p16INK4a detection in head and neck cancers: A systematic review and meta-analysis publication-title: Lancet Oncol. doi: 10.1016/S1470-2045(14)70471-1 contributor: fullname: Ndiaye – volume: 141 start-page: 664 year: 2017 ident: ref_47 article-title: Worldwide burden of cancer attributable to HPV by site, country and HPV type publication-title: Int. J. Cancer doi: 10.1002/ijc.30716 contributor: fullname: Plummer – volume: 107 start-page: S31 year: 2007 ident: ref_10 article-title: Human papillomavirus vaccines and the potential for cross-protection between related HPV types publication-title: Gynecol. Oncol. doi: 10.1016/j.ygyno.2007.08.059 contributor: fullname: Ault – ident: ref_39 doi: 10.3390/vaccines9050410 – volume: 384 start-page: 410 year: 2009 ident: ref_13 article-title: Interaction of human papillomaviruses with the host immune system: A well evolved relationship publication-title: Virology doi: 10.1016/j.virol.2008.10.004 contributor: fullname: Frazer – volume: 344 start-page: e1401 year: 2012 ident: ref_20 article-title: For the FUTURE I and II Study Group, Effect of the human papillomavirus (HPV) quadrivalent vaccine in a subgroup of women with cervical and vulvar disease: Retrospective pooled analysis of trial data publication-title: BMJ doi: 10.1136/bmj.e1401 contributor: fullname: Joura – volume: 54 start-page: 891 year: 2012 ident: ref_34 article-title: Prevention of Recurrent High-Grade Anal Neoplasia with Quadrivalent Human Papillomavirus Vaccination of Men Who Have Sex with Men: A Nonconcurrent Cohort Study publication-title: Clin. Infect. Dis. doi: 10.1093/cid/cir1036 contributor: fullname: Swedish – volume: 18 start-page: 240 year: 2018 ident: ref_5 article-title: Opportunities and challenges for human papillomavirus vaccination in cancer publication-title: Nat. Rev. Cancer doi: 10.1038/nrc.2018.13 contributor: fullname: Roden – volume: 74 start-page: 11636 year: 2000 ident: ref_16 article-title: The Ubiquity and Impressive Genomic Diversity of Human Skin Papillomaviruses Suggest a Commensalic Nature of These Viruses publication-title: J. Virol. doi: 10.1128/JVI.74.24.11636-11641.2000 contributor: fullname: Antonsson – volume: 298 start-page: 1205 year: 2018 ident: ref_25 article-title: Indication of prophylactic vaccines as a tool for secondary prevention in HPV-linked disease publication-title: Arch. Gynecol. Obstet. doi: 10.1007/s00404-018-4926-y contributor: fullname: Pieralli – volume: 161 start-page: 173 year: 2021 ident: ref_37 article-title: High-risk HPV-positive and -negative high-grade cervical dysplasia: Analysis of 5-year outcomes publication-title: Gynecol. Oncol. doi: 10.1016/j.ygyno.2021.01.020 contributor: fullname: Bogani – volume: 160 start-page: 346 year: 2021 ident: ref_36 article-title: Spotlight on the role of human papillomavirus vaccines publication-title: Gynecol. Oncol. doi: 10.1016/j.ygyno.2020.08.034 contributor: fullname: Bogani – volume: 68 start-page: 698 year: 2019 ident: ref_4 article-title: Human Papillomavirus Vaccination for Adults: Updated Recommendations of the Advisory Committee on Immunization Practices publication-title: MMWR Morb. Mortal. Wkly. Rep. doi: 10.15585/mmwr.mm6832a3 contributor: fullname: Meites – ident: ref_43 doi: 10.3390/v13071339 – volume: 36 start-page: 6594 year: 2018 ident: ref_45 article-title: Therapeutic human papillomavirus vaccines in head and neck cancer: A systematic review of current clinical trials publication-title: Vaccine doi: 10.1016/j.vaccine.2018.09.027 contributor: fullname: Schneider |
| SSID | ssj0000913867 |
| Score | 2.3901038 |
| SecondaryResourceType | review_article |
| Snippet | To assess evidence on the efficacy of adjuvant human papillomavirus (HPV) vaccination in patients treated for HPV-related disease across different susceptible... Objective: To assess evidence on the efficacy of adjuvant human papillomavirus (HPV) vaccination in patients treated for HPV-related disease across different... OBJECTIVETo assess evidence on the efficacy of adjuvant human papillomavirus (HPV) vaccination in patients treated for HPV-related disease across different... |
| SourceID | doaj pubmedcentral proquest crossref pubmed |
| SourceType | Open Website Open Access Repository Aggregation Database Index Database |
| StartPage | 239 |
| SubjectTerms | Anogenital anogenital warts Antibodies Bias Cancer cervical cancer Clinical trials Confidence intervals Disease prevention Dysplasia FDA approval Health services HPV Human papillomavirus Infections Meta-analysis Papilloma Patients Penis Public health Risk management Surgery Systematic Review Vaccination Vaccines Vagina vulvar cancer Warts Womens health |
| SummonAdditionalLinks | – databaseName: Directory of Open Access Journals dbid: DOA link: http://sdu.summon.serialssolutions.com/2.0.0/link/0/eLvHCXMwrV1La9wwEB7anHopTdKH26RMoQQKMbEtyZZ7S5uEvbQsZBt6M3qSXrwl3i3kl-TvdiStN7uhkEuPtoQtzYxGM8zMNwAfjWFMuNrlWtgAql2wXBlShlbU3AdwFBubTUwum-8_5dl5gMlZt_oKOWEJHjgR7oQ5zSvNnGWy4ZacCU3fqn3ot8R9W-mofYt6w5mKOrgtmaybFJdk5Nef_FEmRKqHADkaCjq37qEI1_8vG_NhquTG3XPxAp6vjEY8TYvdhSeu34OjaUKdvj3G2X0R1XCMRzi9x6O-3Ye7yfQKr-LCIhsw9gXHacKZwNmYao5zjzQ1j_lxzuJZit2gijugx9RKZYGxfhMvyVgdPuMpxhrezepeDErmxl2n3HhM4QdUvcVvbqHyEQflJfy4OJ99neSrfgy54W2xyJVgzlTCGrI6SDcJy6z3XLpQrFtYL1TZtl6VpSo1JytLaleSWvesMrUzltTHK9jp5717A7RREoaiMq3RmpMF1paeaOwLK23llSsy-DRyp_udyNGRuxI42T3kZAZfAvvW8wJgdnxBYtStxKh7TIwyOBiZ361O8dBVNTnwPASmM_iwHqbzF4Iqqnfz5ThHSiEzeJ1kZb0SMm7pImqbDJotKdpa6vZI_-s6YnwTfem34u3_2Ns7eFaFoo2Qa84PYGdxs3SH8HSwy_fx1PwFDr0iJg priority: 102 providerName: Directory of Open Access Journals |
| Title | HPV Vaccination after Primary Treatment of HPV-Related Disease across Different Organ Sites: A Multidisciplinary Comprehensive Review and Meta-Analysis |
| URI | https://www.ncbi.nlm.nih.gov/pubmed/35214697 https://www.proquest.com/docview/2633842964 https://search.proquest.com/docview/2633848858 https://pubmed.ncbi.nlm.nih.gov/PMC8879645 https://doaj.org/article/3eb42b3ed3874d448bac16f31684f92b |
| Volume | 10 |
| hasFullText | 1 |
| inHoldings | 1 |
| isFullTextHit | |
| isPrint | |
| link | http://sdu.summon.serialssolutions.com/2.0.0/link/0/eLvHCXMwnV1La9tAEB7qHEoupe-qTcMUSqAQxZJ2JUu9pXngS4ohbuhN7DMJNHKw7EB-Sf5uZ3clxw499SjtCnZ3HjujmfkG4KtSjOWmMLHMtQPVTlgsFClDnRfcOnAU7ZtNjM9HP3-XxycOJifva2F80r6S1wfNn5uD5vrK51be3qhhnyc2nJwdkWBUBc-HAxiQbbjmonv1W6WsLEYhJMnIpR_eCeWC1K1DG3W1nNvwnMwOUhEO6WntNvKg_f-yNJ8mTK7dQKcv4UVnOuJhWOIreGaa17A3CdjT9_s4fSylavdxDyePqNT3b-BhPLnAC79GTwz03cFxEtAmcNonnOPMIk2NfZac0XgcIjgo_A7oMTRUWaCv4sRzMlnb73iIvpJ3vcYXnaqZm6uQIY8hCIGi0XhmFiLu0VDewq_Tk-nROO66MsSKV8kiFjkzKsu1ItuDCJFrpq3lpXElu4m2uUiryoo0FankZGuV0qSk3C3LVGGUJiXyDraaWWM-AG2UWCLJVKWk5GSHVamlM7aJLnVmhUki-NZTp74Nx1GT0-KIWj8lagQ_HPlW8xxstn8xm1_WHfPUzEieSWY0K0dck2cqiTEL65p3cVtlMoKdnvh1J8ttnRXkxnMXno7gy2qYpNCFVkRjZst-TlnmZQTvA6-sVtLzWgSjDS7aWOrmCDG-R_ruGP3jf3_5CbYzV6_h0sz5Dmwt5kvzGQatXu76vw-7Xnb-AmnQI54 |
| link.rule.ids | 230,315,729,782,786,866,887,2106,27933,27934,53800,53802 |
| linkProvider | National Library of Medicine |
| linkToHtml | http://sdu.summon.serialssolutions.com/2.0.0/link/0/eLvHCXMwnV3da9swED_WDra-dN-rt27TYBQGdWNbsiPvresHGWtKoFnZm9HnWlidEieD_iX7d3eS7DQpe-qjLRkk3-9OJ-7udwCflKI0N4WJZa4dqXZCY6HQGOq8YNaRo2jfbGJw1j_9yQ-PHE1O3tXC-KR9JS_36t9Xe_Xlhc-tvL5SvS5PrDcaHqBilAXLe2vwEPU1SZYu6d4AlynlRT8EJSle6nt_hHJh6sbxjbpqzg14hI4HGgnH9bR0Hnna_v_5mndTJpfOoOMn91z9U9hsnU6yH4afwQNTP4edUWCtvtkl49sirGaX7JDRLZ_1zQv4Oxidk3O_Ny9G4vuKk1HgqSDjLlWdTCzBqbHPrzOaHIbYDxF-5_gYWrHMiK__JGfo7DZfyD7xNcDL1cHEGampuQi59SSEL4ioNRmamYg7HpWX8OP4aHwwiNt-DrFiZTKLRU6NynKt0GvBn5Brqq1l3Lhi30TbXKRlaUWailQy9NK4NCkeC5ZmqjBKo_l5Bev1pDZbgBtFMCWZKpWUDD24MrUoG5torjMrTBLB506q1XX4HRVedxwYqrtgiOCrE_tiniPc9i8m019VK7iKGskySY2mvM803mklQrqwru0Xs2UmI9juQFO1VqCpsoJSzlxgO4KPi2HUXxeUEbWZzLs5nOc8gtcBY4uVdBiNoL-CvpWlro4g6DxHeAuyN_f-8gM8HoyHJ9XJt9Pvb2EjsFVkccK2YX02nZt3sNbo-Xuvef8AdKU4Vg |
| linkToPdf | http://sdu.summon.serialssolutions.com/2.0.0/link/0/eLvHCXMwpV3db9MwED-xIU17YXyOjAFGQpOQluXDTprwNtZVRbAp0srEW-RPNomlVdMi7S_h3-VsN1078QSPSS6S7fv5fNbd_Q7gvZSUZjrXociUJdWOacglGkOV5cxYchTlmk0ML3rn34v-qaXJWbb6ckn7UlwfNT9vjprrK5dbObmRUZcnFlVnJ7gxypxl0USZaAMe4p6N05WLujPCZUKLvOcDkxQv9tEvLm2ourWco7aicxu20PlAQ2H5nlbOJEfd_zd_837a5Mo5NNj5jxk8hkcL55Mce5En8EA3T-Gg8uzVt4dkdFeM1R6SA1Ld8VrfPoPfw-qSXLr5OXUS11-cVJ6vgoy6lHUyNgRFQ5dnpxXp-xgQ4W72-OhbssyIqwMlF-j0th_JMXG1wKtVwsQaq6m-8jn2xIcxCG8UOdMzHnZ8Ks_h2-B0dDIMF30dQsnKeBbyjGqZZkqi94ILkSmqjGGFtkW_sTIZT8rS8CThiWDorRVCJ3g8GJrKXEuFZugFbDbjRr8EnCiCKk5lKYVg6MmViUH9mFgVKjVcxwF86DRbT_xy1HjtsYCo7wMigE9W9Us5S7ztXoynP-qF8mqqBUsF1YoWPabwbisQ2rmx7b-YKVMRwH4HnHphDdo6zSktmA1wB_Bu-Rn3sQ3O8EaP551MUWRFALseZ8uRdDgNoLeGwLWhrn9B4Dmu8AXQ9v75z7ewVfUH9dfP519ewXZqiz9szjrbh83ZdK5fw0ar5m_c5vsDBP86wA |
| openUrl | ctx_ver=Z39.88-2004&ctx_enc=info%3Aofi%2Fenc%3AUTF-8&rfr_id=info%3Asid%2Fsummon.serialssolutions.com&rft_val_fmt=info%3Aofi%2Ffmt%3Akev%3Amtx%3Ajournal&rft.genre=article&rft.atitle=HPV+Vaccination+after+Primary+Treatment+of+HPV-Related+Disease+across+Different+Organ+Sites%3A+A+Multidisciplinary+Comprehensive+Review+and+Meta-Analysis&rft.jtitle=Vaccines+%28Basel%29&rft.au=Di+Donato%2C+Violante&rft.au=Caruso%2C+Giuseppe&rft.au=Bogani%2C+Giorgio&rft.au=Cavallari%2C+Eugenio+Nelson&rft.date=2022-02-04&rft.issn=2076-393X&rft.eissn=2076-393X&rft.volume=10&rft.issue=2&rft_id=info:doi/10.3390%2Fvaccines10020239&rft.externalDBID=NO_FULL_TEXT |
| thumbnail_l | http://covers-cdn.summon.serialssolutions.com/index.aspx?isbn=/lc.gif&issn=2076-393X&client=summon |
| thumbnail_m | http://covers-cdn.summon.serialssolutions.com/index.aspx?isbn=/mc.gif&issn=2076-393X&client=summon |
| thumbnail_s | http://covers-cdn.summon.serialssolutions.com/index.aspx?isbn=/sc.gif&issn=2076-393X&client=summon |